fda bpc-157 warning letter or statement issued 25 letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, of FDA Targets GLP-1 and Peptide

In some embodiments, the otic composition or formulation comprises less than 7% by weight of C1-C6 alcohols or C1-C6 glycols

Huang Z, Wong L-W, Su Y, Huang X, Wang N, Chen H, et al

the broader metabolic case is being built through the CagriSema combination rather than cagrilintide alone

Even more intriguing is the presentation of right forelimb sparing and disability (reacting with only left or no forelimb upon challenge with forceps have difficulty with maintaining body balance while rearing), common in cuprizone rats, not presented in BPC 157-cuprizone rats (normal functioning of right forelimb, simultaneous reaction with both forelimbs, and grasp the forceps, and maintain body balance while rearing as healthy rats)